Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cloxacillin Sodium

FDA-approved product (for solution, oral), marketed as Cloxacillin Sodium, Cloxapen, Tegopen.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Cloxacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF02

Repurposing investigation

Cloxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 1 of 1 lab record
Open Cloxacillin Sodium in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cloxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Aminoglycosides in Early Sepsis

    NCT06712641 · start 2026-04-23

    Registered record
    Registry ID
    NCT06712641
    Conditions
    Sepsis
    Interventions
    Gentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-23
    Completion
    2033-05
    Enrolment
    1,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionGentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    PhasePhase 4
    Registry statusRecruiting

  • Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia

    NCT06726395 · start 2025-03-10

    Registered record
    Registry ID
    NCT06726395
    Conditions
    Staphylococcus Aureus Bacteraemia; Staphylococcal Bacteraemia; Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia); Staphylococcus (S.) Aureus Infection
    Interventions
    Penicillin G_1200mg; cloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-03-10
    Completion
    2028-07
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteraemia; Staphylococcal Bacteraemia; Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) +1 more
    InterventionPenicillin G_1200mg; cloxacillin
    PhasePhase 4
    Registry statusRecruiting

  • Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

    NCT06695832 · start 2024-11-01

    Registered record
    Registry ID
    NCT06695832
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-11-01
    Completion
    2025-01-31
    Enrolment
    369

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study)

    NCT06505135 · start 2024-09-03

    Registered record
    Registry ID
    NCT06505135
    Conditions
    Rotator Cuff Tears; Rotator Cuff Injuries; Rotator Cuff Tear Arthropathy
    Interventions
    Stem-cell treatment; Standard care
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Enrolling by invitation
    Start
    2024-09-03
    Completion
    2026-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRotator Cuff Tears; Rotator Cuff Injuries; Rotator Cuff Tear Arthropathy
    InterventionStem-cell treatment; Standard care
    PhasePhase 1
    Registry statusEnrolling by invitation

  • Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia

    NCT06336824 · start 2024-06-28

    Registered record
    Registry ID
    NCT06336824
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-28
    Completion
    2025-06
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionTab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    PhasePhase 3
    Registry statusUnknown

  • Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

    NCT05899140 · start 2024-03-15

    Registered record
    Registry ID
    NCT05899140
    Conditions
    Skin Infection; Staphylococcal Infections; Staphylococcus Aureus Infection
    Interventions
    Clindamycin; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-03-15
    Completion
    2026-07-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infection; Staphylococcal Infections; Staphylococcus Aureus Infection
    InterventionClindamycin; Standard of care
    PhasePhase 4
    Registry statusRecruiting

  • Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis

    NCT05578482 · start 2022-10-24

    Registered record
    Registry ID
    NCT05578482
    Conditions
    Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis Flare
    Interventions
    Dicloxacillin Oral Capsule; Elocon 0.1 % Topical Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-10-24
    Completion
    2023-05
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis Flare
    InterventionDicloxacillin Oral Capsule; Elocon 0.1 % Topical Cream
    PhasePhase 4
    Registry statusUnknown

  • Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture

    NCT05530174 · start 2022-09-01

    Registered record
    Registry ID
    NCT05530174
    Conditions
    Fracture of Hip; Total Hip Arthroplasty; Prosthetic-joint Infection; Fracture Acetabular
    Interventions
    Antibiotic dosage practice
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2022-09-01
    Completion
    2025-04-01
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFracture of Hip; Total Hip Arthroplasty; Prosthetic-joint Infection; Fracture Acetabular
    InterventionAntibiotic dosage practice
    PhaseNot applicable
    Registry statusActive not recruiting

  • Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

    NCT05398679 · start 2022-08-17

    Registered record
    Registry ID
    NCT05398679
    Conditions
    Endocarditis Infective
    Interventions
    Cefaclor; Ciprofloxacin Tablets; Ciprofloxacin Injection; Clindamycin Oral Capsule; Clindamycin Injection; Dicloxacillin Oral Capsule; Dicloxacillin; Fusidic Acid Only Product in Oral Dose Form; Fusidic Acid Only Product in Parenteral Dose Form; Levofloxacin Oral Tablet; Levofloxacin Injection; Linezolid Oral Tablet; Linezolid Injectable Product; Moxifloxacin tablet; Moxifloxacin Injectable Product; Rifampicin Only Product in Oral Dose Form; Rifampicin Only Product in Parenteral Dose Form; Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]; Sulfamethoxazole / Trimethoprim Injectable Product; Tedizolid Oral Tablet; Tedizolid Injection; Amoxicillin Capsules; Amoxicillin; Cefaclor Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-08-17
    Completion
    2027-12-30
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis Infective
    InterventionCefaclor; Ciprofloxacin Tablets; Ciprofloxacin Injection; Clindamycin Oral Capsule +20 more
    PhasePhase 4
    Registry statusRecruiting

  • Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

    NCT05156437 · start 2022-03-16

    Registered record
    Registry ID
    NCT05156437
    Conditions
    Endocarditis
    Interventions
    Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin; Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-03-16
    Completion
    2024-10-31
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis
    InterventionAmoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin; Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
    PhasePhase 4
    Registry statusTerminated

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting

  • The Effect of Dicloxacillin on Oral Absorption of Drugs

    NCT05073627 · start 2022-02-07

    Registered record
    Registry ID
    NCT05073627
    Conditions
    Healthy Volunteers; Drug-drug Interaction
    Interventions
    Dicloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-02-07
    Completion
    2022-06-22
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Drug-drug Interaction
    InterventionDicloxacillin
    PhasePhase 1
    Registry statusCompleted

  • Renal Tolerance of Amoxicillin and Cloxacillin Combination

    NCT05142891 · start 2021-10-15

    Registered record
    Registry ID
    NCT05142891
    Conditions
    Endocarditis; Acute Kidney Injury
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-10-15
    Completion
    2022-10-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis; Acute Kidney Injury
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Metabolic and Metagenomic Effects of Intestinal Microbiome Repopulation in Unexplained Atherosclerosis

    NCT04410003 · start 2020-06-02

    Registered record
    Registry ID
    NCT04410003
    Conditions
    Atherosclerosis; Intestinal Microbiome
    Interventions
    Fecal microbial transplant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2020-06-02
    Completion
    2025-07-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Intestinal Microbiome
    InterventionFecal microbial transplant
    PhasePhase 1
    Registry statusRecruiting

  • Gentamicin in Cardiac Surgery

    NCT06454643 · start 2020-01-01

    Registered record
    Registry ID
    NCT06454643
    Conditions
    Cardiac Infection
    Interventions
    Flucloxacillin and gentamicin; Flucloxacillin and ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2021-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Infection
    InterventionFlucloxacillin and gentamicin; Flucloxacillin and ceftriaxone
    PhaseNot applicable
    Registry statusCompleted